Clinical Trials Arena on MSN
MSD and Eisai to end Phase III LEAP-012 trial for unresectable HCC
M erck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...
MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA ® (pembrolizumab), Merck’s ...
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and ...
(Reuters) -Alliance Laundry is targeting a valuation of up to $4.34 billion in its U.S. initial public offering, the commercial laundry equipment maker said on Monday, as the frenzy around first-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback